Qin Tingting, Xiang Wanping, Mao Yiming, Zhai Hongyan, Yang Zhihao, Zhang Hongpan
Department of Oncology, Wuhan Third Hospital, Wuhan, Hubei, China.
North Sichuan Medical College, Nanchong, Sichuan, China.
Front Oncol. 2023 Jan 4;12:1025192. doi: 10.3389/fonc.2022.1025192. eCollection 2022.
Recent discoveries have suggested that the F-actin capping protein α1 subunit (CAPZA1) in various human tumors could play a significantly important role in regulating cell proliferation, metastasis, and epithelial-mesenchymal transition. However, the immune-regulating role of CAPZA1 in the initiation and development of lung adenocarcinoma (LUAD) remains unclear. In our research, we first found that CAPZA1 serves as an oncogene in pan-cancers from the TCGA data and higher CAPZA1 expression process unfavorably prognostic value in LUAD based on starBase database, PrognoScan, and LOGpc database. Then, in our analyses, lncRNAs AC026356.1 in LUAD acted as a competitive endogenous RNA (ceRNA) of miR-30d-5p, which might be the possible regulatory miRNA of CAPZA1 based on the starBase database. Finally, we confirmed that CAPZA1 expression had a tightly positive correlation with immune infiltration cells, immune infiltration markers, TMB, MSI, immune score, stromal score, and immune checkpoints, indicating that CAPZA1 was a markedly reliable therapeutic target for immunological antitumor strategies. In conclusion, our investigations revealed that CAPZA1 might function as an immune-associated biomarker in the development and treatment of LUAD, thereby acting as a promising prognostic and therapeutic target against LUAD.
最近的研究发现表明,F-肌动蛋白封端蛋白α1亚基(CAPZA1)在多种人类肿瘤中可能在调节细胞增殖、转移和上皮-间质转化方面发挥极其重要的作用。然而,CAPZA1在肺腺癌(LUAD)发生和发展中的免疫调节作用仍不清楚。在我们的研究中,我们首先从TCGA数据中发现CAPZA1在泛癌中作为一种癌基因,并且基于starBase数据库、PrognoScan和LOGpc数据库,CAPZA1的高表达在LUAD中具有不良预后价值。然后,在我们的分析中,LUAD中的lncRNAs AC026356.1作为miR-30d-5p的竞争性内源RNA(ceRNA),基于starBase数据库,miR-30d-5p可能是CAPZA1的潜在调控miRNA。最后,我们证实CAPZA1的表达与免疫浸润细胞、免疫浸润标志物、肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)、免疫评分、基质评分和免疫检查点呈紧密正相关,表明CAPZA1是免疫抗肿瘤策略中一个显著可靠的治疗靶点。总之,我们的研究表明,CAPZA1可能在LUAD的发生发展和治疗中作为一种免疫相关生物标志物,从而成为对抗LUAD的一个有前景的预后和治疗靶点。